A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary and study completion dates changed from estimate of Sep 2026 to Sep 14, 2026
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 3 of 8 entries
  2. Enrollment closed, study ongoing
    • Primary and study completion pushed from Jul 2026 to Sep 2026
    • Site details revised
    v4
  3. Enrollment increased: 36 → 58 participants
    • Primary completion pushed from Jun 2026 to Jul 2026
    v3
  4. Recruitment opened
    • Start date changed from estimate of Mar 2026 to Apr 14, 2026
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.
Trial Details
NCT Number NCT07479641
Lead Sponsor Shandong Suncadia Medicine Co., Ltd.
Conditions
(from sponsor)		 Cardiomyopathy
Related terms Cardiomyopathies
Enrollment 58 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov